Drug Overview

Selinexor is a first-in-class, modern cancer medication used to treat specific types of blood cancers that have returned or are no longer responding to standard treatments. It belongs to a unique group of drugs that control how proteins move inside a cell. By keeping natural “cancer-fighting” proteins where they are needed most, this medicine helps the body stop tumors from growing.

Selinexor is a prescription medication that is taken as a tablet. Because it targets a very specific process inside the cell, it is often used in combination with other low-dose steroids or cancer drugs to increase its effectiveness.

• Generic name: Selinexor
• US Brand names: XPOVIO
• Drug Class: Selective Inhibitor of Nuclear Export (SINE), Exportin 1 (XPO1) inhibitor
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

Selinexor is a prime example of a Targeted Therapy and is often referred to as a Smart Drug. Unlike traditional chemotherapy that attacks all fast-growing cells, selinexor targets a specific transport protein that cancer cells use to survive.

At the molecular level, every cell has a center called the nucleus, which acts like a control room. Inside this control room, the body keeps “tumor suppressor proteins.” These proteins are like security guards; their job is to find damage in the cell and either fix it or tell the cell to die so it does not become a tumor.

Cancer cells find a way to “kidnap” these security guards and kick them out of the control room. They do this using a transport protein called Exportin 1 (XPO1). XPO1 acts like an exit door, carrying the tumor suppressor proteins out of the nucleus where they can no longer do their job.

Selinexor works by binding directly to the XPO1 protein and “locking the exit door.” By blocking XPO1, selinexor forces the tumor suppressor proteins to stay inside the nucleus. Once these guard proteins build up to high levels, they can successfully detect the cancer and force the sick cell to go through apoptosis (programmed cell death), while leaving healthy cells mostly alone.

FDA-Approved Clinical Indications

Oncological uses

• Multiple Myeloma: Used in combination with dexamethasone for adult patients who have received at least four prior therapies.
• Multiple Myeloma: Used in combination with bortezomib and dexamethasone for patients who have received at least one prior therapy.
• Diffuse Large B-Cell Lymphoma (DLBCL): Used for adult patients with relapsed or refractory disease after at least two lines of systemic therapy.

Non-oncological

• None at this time.

Dosage and Administration Protocols

The dosage of selinexor varies significantly based on the condition being treated and whether it is used alone or with other drugs.

Dose Adjustments

If a patient develops severe side effects, the doctor may reduce the dose (for example, from 80 milligrams down to 60 milligrams). Selinexor does not require specific dose starting adjustments for mild to moderate renal (kidney) or hepatic (liver) insufficiency, but patients with severe impairment must be monitored closely for toxicity.

Clinical Efficacy and Research Results

Clinical data from 2020 to 2025 has confirmed that selinexor provides a significant survival benefit for patients with limited options.

In the BOSTON Phase 3 trial, patients with multiple myeloma who took selinexor along with bortezomib and dexamethasone lived significantly longer without their disease getting worse. The numerical data showed a 30 percent reduction in the risk of disease progression compared to patients only taking standard therapy. The median progression-free survival was 13.9 months for the selinexor group versus 9.5 months for the control group.

In the SADAL study for lymphoma (DLBCL), the overall response rate was 29 percent, with several patients achieving a complete disappearance of their tumors. This is considered a strong result for patients who had already failed multiple other types of treatment.

Safety Profile and Side Effects

Selinexor is a powerful drug and requires careful management of side effects, particularly during the first two months of treatment.

Black Box Warning

Selinexor does not currently have an official FDA Black Box Warning.

Common side effects

These occur in greater than 10 percent of patients:

• Nausea and vomiting
• Loss of appetite and weight loss
• Diarrhea or constipation
• Feeling very tired (fatigue)
• Low blood platelet counts (thrombocytopenia)
• Low sodium levels in the blood (hyponatremia)

Serious adverse events

• Severe thrombocytopenia (dangerously low platelets increasing bleeding risk)
• Neurological issues (confusion, dizziness, or fainting)
• Severe infections (pneumonia or sepsis)
• Blurred vision or cataracts

Management strategies

To manage nausea, doctors often prescribe “around-the-clock” anti-nausea medicine for the first few weeks. If a patient loses too much weight, nutritional counseling and appetite stimulants are used. For low blood counts, doctors may pause the treatment or provide a platelet transfusion.

Research Areas

Research Areas

Selinexor is currently being studied for use in “maintenance therapy” after a stem cell transplant to prevent cancer from coming back. Because it helps maintain tumor suppressor proteins, researchers are investigating if it can keep the newly transplanted immune system “alert” and more effective at catching any leftover cancer cells. It is also being studied in combination with new immunotherapies to see if it makes them work better against solid tumors.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Complete blood count (CBC) to check platelets and white blood cells.
• Blood chemistry panel to check sodium and liver function.
• Baseline body weight measurement.
• Baseline eye exam (to monitor for future cataracts).

Precautions during treatment

Patients must be very careful to stay hydrated. Because the drug can cause confusion or dizziness, patients should not drive or use heavy machinery if they feel lightheaded. Frequent blood tests (often once a week at the start) are necessary to stay safe.

Do’s and Don’ts list

• Do drink at least 6 to 8 glasses of water a day to prevent dehydration.
• Do take your anti-nausea medication exactly as your doctor tells you, even if you do not feel sick yet.
• Do monitor your weight at home and report any sudden loss to your care team.
• Don’t skip doses or change your schedule without talking to your oncologist.
• Don’t ignore signs of infection, such as a fever or chills.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Selinexor (XPOVIO) is a prescription medication used under the strict supervision of trained medical professionals and oncologists. Always consult with a qualified healthcare professional before starting any new treatment, changing your medication regimen, or if you have questions regarding your specific medical condition or cancer treatment plan.